AN2 Therapeutics Inc (ANTX) — Cash Flow-to-Debt Ratio
Latest as of June 2026:
-1.22x
AN2 Therapeutics Inc (ANTX) has a Cash Flow-to-Debt Ratio of -1.22x as of June 2026, meaning its operating cash flow of $-7.00 Million could theoretically repay -1% of its total liabilities ($5.75 Million) in one year. See financial flexibility index of AN2 Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-1.22x
Operating CF / Total Liabilities
Operating Cash Flow
$-7.00 Million
USD
Total Liabilities
$5.75 Million
USD
Data as of
Jun 2026
Most recent filing
AN2 Therapeutics Inc Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for AN2 Therapeutics Inc across 7 annual periods. For the full cash flow conversion analysis, see AN2 Therapeutics Inc (ANTX) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for AN2 Therapeutics Inc (2019–2025)
Year-by-year debt coverage analysis for AN2 Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.36x | $-29.83 Million | $8.89 Million | ▲ +30.2% |
| 2024 | -4.81x | $-49.26 Million | $10.24 Million | ▼ -26.8% |
| 2023 | -3.79x | $-53.29 Million | $14.04 Million | ▲ +18.5% |
| 2022 | -4.66x | $-33.46 Million | $7.19 Million | ▲ +22.5% |
| 2021 | -6.01x | $-20.48 Million | $3.41 Million | ▼ -66.2% |
| 2020 | -3.62x | $-5.36 Million | $1.48 Million | ▼ -29.1% |
| 2019 | -2.80x | $-2.49 Million | $887.00K | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.